Theralase's Lead Anti-Cancer Drug Has Significantly Less Skin Toxicity than FDA Approved Drug

Toronto, ON  / February 13, 2015 / Theralase Technologies Inc. ("Theralase") (TLT:TSXV) (TLTFF: OTC Pink(R)), a developer of advanced Photo Dynamic Therapy ("PDT"), for serious and life-threatening diseases, announced today that research on its Anti-Cancer Technology ("ACT") platform involving its lead Photo Dynamic Compound ("PDC") TLD-1433 has shown that it has significantly less skin toxicity than the Food and Drug Administration ("FDA") approved PDC Photofrin(R).

Photofrin(R) has been documented to induce skin sensitivity in patient's treated with the PDC to sunlight or bright lights after administration. Patients who receive Photofrin(R) will be photosensitive and must strictly avoid exposure of skin and eyes to direct sunlight or bright indoor light (i.e.: examination lamps, dental lamps, operating room lamps, unshaded light bulbs at close proximity, etc.) for at least 30 days post treatment. Some patients may remain photosensitive for up to 90 days or more. The photosensitivity is due to residual traces of the drug, which will be present in all parts of the skin. This necessitates the patient to stay indoors after treatment to prevent potential skin damage.

Cytokinetics Reports 4th Quarter 2014 Financial Results

Ongoing Regulatory Interactions in US and Europe Inform Progression of Tirasemtiv to Phase III

COSMIC-HF Nears Completion of Enrollment with Results Expected Later This Year

Company Exceeded Financial Guidance in 2014 and Provides Milestones and Financial Guidance for 2015

SOUTH SAN FRANCISCO, CA, February 12, 2015 - Cytokinetics, Incorporated (CYTK) reported total research and development revenues for the fourth quarter of 2014 were $21.8 million, compared to $24.3 million during the same period in 2013.  The net income for the fourth quarter was $8.4 million, or $0.23 per basic and diluted share. This is compared to a net income for the same period in 2013, of $6.5 million, or $0.22 per basic share and $0.21 per diluted share. As of December 31, 2014, cash, cash equivalents and investments totaled $83.2 million, which includes the receipt of $10 million for the sale of common stock to Astellas Pharma Inc., but does not include $45.0 million received from Astellas in January 2015.  With the recognition of a milestone payment under its collaboration agreement with Astellas, the company exceeded its 2014 financial guidance.

Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Designation from the U.S. FDA for Ovarian Cancer

CALGARY, Feb. 11, 2015 - Oncolytics Biotech^® Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY), a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its lead product candidate, REOLYSIN^®, for the treatment of ovarian cancer.

"This is an important regulatory milestone for Oncolytics and will provide us with a number of benefits as we advance the development and commercialization process for REOLYSIN^®," said Dr. Brad Thompson, President and CEO of Oncolytics. "Ovarian cancer is a devastating disease that represents a significant unmet need, particularly for those patients diagnosed in later stages."

Advaxis Forms Clinical Trial Collaboration With Incyte to Evaluate Investigational Combination of Two Novel Cancer Immunotherapies for Early Stage Cervical Cancer

PRINCETON, N.J., Feb. 11, 2015 -- Advaxis, Inc. (ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, has entered into a clinical trial collaboration agreement with Incyte Corporation (INCY) to evaluate the combination of Advaxis's Lm-LLO cancer immunotherapy, ADXS-HPV (ADXS11-001), with Incyte's investigational oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, epacadostat (INCB24360). The Phase 2 multicenter, open-label, preoperative window-study will evaluate the safety and efficacy of ADXS-HPV as a monotherapy and in combination with epacadostat in approximately 20 patients with Stage I-IIa human papillomavirus (HPV)-associated cervical cancer.